drugset / Trial / NCT05467670
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Phase 2
Active not recruiting
16 enrolled
Alexander B Olawaiye, MD
ALX Oncology Inc. · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).
Timeline
- Start
- 2023-03-30
- Primary completion
- 2026-04-22
- Completion
- 2031-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evorpacept | Protein / enzyme biologic | 45 mg/kg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |